<table width="100%" xmlns="urn:hl7-org:v3" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<col width="44%"></col>
<col width="38%"></col>
<tbody>
<tr>
<td stylecode="Rrule Botrule Lrule Toprule " valign="top">
<paragraph>
<content stylecode="bold">Factors</content>
</paragraph>
</td>
<td stylecode="Rrule Botrule Lrule Toprule " valign="top">
<paragraph>
<content stylecode="bold">Adjusted Dose</content>
</paragraph>
</td>
</tr>
<tr>
<td stylecode="Rrule Lrule Botrule " valign="top">
<paragraph>
<content stylecode="bold">CYP2D6 Poor Metabolizers</content>
</paragraph>
</td>
<td stylecode="Rrule Lrule Toprule Botrule " valign="top"></td>
</tr>
<tr>
<td stylecode="Rrule Lrule Botrule " valign="top">
<paragraph>CYP2D6 Poor Metabolizers taking concomitant CYP3A4 inhibitors</paragraph>
</td>
<td stylecode="Rrule Lrule Toprule Botrule " valign="top">
<paragraph>200 mg<footnote id="_Ref447799937">200 mg and 160 mg dose adjustments are obtained only by using the 300 mg or 400 mg strength vials.</footnote>
</paragraph>
</td>
</tr>
<tr>
<td stylecode="Rrule Lrule Botrule " valign="top">
<paragraph>
<content stylecode="bold">Patients Taking 400 mg of ABILIFY MAINTENA</content>
</paragraph>
</td>
<td stylecode="Rrule Lrule Toprule Botrule " valign="top"></td>
</tr>
<tr>
<td stylecode="Rrule Lrule Botrule " valign="top">
<paragraph>Strong CYP2D6 <content stylecode="bold">
<content stylecode="underline">or</content>
</content> CYP3A4 inhibitors</paragraph>
</td>
<td stylecode="Rrule Lrule Toprule Botrule " valign="top">
<paragraph>300 mg</paragraph>
</td>
</tr>
<tr>
<td stylecode="Rrule Lrule Botrule " valign="top">
<paragraph>CYP2D6 <content stylecode="bold">
<content stylecode="underline">and </content>
</content>CYP3A4 inhibitors</paragraph>
</td>
<td stylecode="Rrule Lrule Toprule Botrule " valign="top">
<paragraph>200 mg<footnoteref idref="_Ref447799937"></footnoteref>
</paragraph>
</td>
</tr>
<tr>
<td stylecode="Rrule Lrule Botrule " valign="top">
<paragraph>CYP3A4 inducers</paragraph>
</td>
<td stylecode="Rrule Lrule Toprule Botrule " valign="top">
<paragraph>Avoid use</paragraph>
</td>
</tr>
<tr>
<td stylecode="Rrule Lrule Botrule " valign="top">
<paragraph>
<content stylecode="bold">Patients Taking 300 mg of ABILIFY MAINTENA</content>
</paragraph>
</td>
<td stylecode="Rrule Lrule Toprule Botrule " valign="top"></td>
</tr>
<tr>
<td stylecode="Rrule Lrule Botrule " valign="top">
<paragraph>Strong CYP2D6 <content stylecode="bold">
<content stylecode="underline">or </content>
</content>CYP3A4 inhibitors</paragraph>
</td>
<td stylecode="Rrule Lrule Toprule Botrule " valign="top">
<paragraph>200 mg<footnoteref idref="_Ref447799937"></footnoteref>
</paragraph>
</td>
</tr>
<tr>
<td stylecode="Rrule Lrule Botrule " valign="top">
<paragraph>CYP2D6 <content stylecode="bold">
<content stylecode="underline">and</content>
</content> CYP3A4 inhibitors</paragraph>
</td>
<td stylecode="Rrule Lrule Toprule Botrule " valign="top">
<paragraph>160 mg<footnoteref idref="_Ref447799937"></footnoteref>
</paragraph>
</td>
</tr>
<tr>
<td stylecode="Rrule Botrule Lrule Toprule " valign="top">
<paragraph>CYP3A4 inducers</paragraph>
</td>
<td stylecode="Rrule Botrule Lrule Toprule " valign="top">
<paragraph>Avoid use</paragraph>
</td>
</tr>
</tbody>
</table>